Evidence map›Paper›PMID 27722974›Full record

Trial reportJournal of medical systems2016

Type 2 Diabetes Patients Benefit from the COMODITY12 mHealth System: Results of a Randomised Trial.

Przemysław Kardas, Krzysztof Lewandowski, Stefano Bromuri

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of medical systems, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Przemysław KardasI Department of Family Medicine, Medical University of Lodz, Lodz, Poland. przemyslaw.kardas@umed.lodz.pl.ORCID http://orcid.org/0000-0002-6078-2628
Krzysztof LewandowskiDepartment of Endocrinology & Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
Stefano BromuriManagement Science and Technology, Open University of the Netherlands, Heerlen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient acceptance is one of the major barriers toward widespread use of mHealth systems. The aim of this study was to assess system operability and whole trial feasibility, including patients' experience with their use of COMMODITY12 mHealth system under. Secondary study aims included assessment of several metabolic parameters as well as patient adherence to the treatment. This was a prospective parallel-arm randomized controlled trial in outpatients diagnosed with DM2, being treated in the primary care settings in Lodz region, Poland, with 6 weeks period of follow-up. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5 L questionnaire, assessing health-related quality of life. Sixty patients (female, 24, male, 36, mean age +/- SD 59.5 +/- 6.8) completed study. All four layers of the COMMODITY12 system proved to work smooth under real-life conditions, without major problems. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with cumulative utility measure, improved significantly in COMMODITY12 system users (P < 0.05). mHealth system modestly improved glycaemic and blood pressure control, assuring high level of patient adherence with overall adherence reaching 92.9 %. Study proved that the COMODITY12 system is well accepted by type 2 diabetes patients taking part in clinical trial, leading to several clinical benefits, and improved quality of life. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed.

Indexed as

Patient Acceptance of Health CareAccelerometryAgedBlood GlucoseCost-Benefit AnalysisDiabetes Mellitus, Type 2ElectrocardiographyFemaleHeart RateHumansHypoglycemic AgentsMaleMedication AdherenceMiddle AgedPolandPrimary Health CareBlood GlucoseHypoglycemic AgentsCOMODITY12DiabetesHealth-related quality of lifeMedication adherencemHealth

Identifiers

PMID27722974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.